Relay Therapeutics reported a net margin of -23,916.86% for the quarter ended Jun 2026. These financial ratios cover 26 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2019 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||||
| EBT Margin | -9,134.08% | -12,246.56% | -16,914.56% | -22,054.52% | -24,470.64% | -27,621.34% | -41,698.67% | -82,765.55% | -260.82% | 8,349,600.00% | -813.55% | -1,003.58% | -10,301.62% | -784.57% | -2,443.03% | -23,916.86% | ||||||||||
| EBIT Margin | -9,157.66% | -11,944.09% | -14,969.21% | -21,318.08% | -24,968.60% | -28,794.86% | -44,768.58% | -89,117.65% | -291.95% | 9,219,600.00% | -903.00% | -1,105.21% | -11,351.11% | -866.14% | -2,619.67% | -25,949.71% | ||||||||||
| EBITDA Margin | -9,157.66% | -11,944.09% | -14,969.21% | -21,318.08% | -24,968.60% | -28,794.86% | -44,768.58% | -89,117.65% | -291.95% | 9,219,600.00% | -903.00% | -1,105.21% | -11,351.11% | -866.14% | -2,619.67% | -25,949.71% | ||||||||||
| Operating Margin | -9,157.66% | -11,944.09% | -14,969.21% | -21,318.08% | -24,968.60% | -28,794.86% | -44,768.58% | -89,117.65% | -291.95% | 9,219,600.00% | -903.00% | -1,105.21% | -11,351.11% | -866.14% | -2,619.67% | -25,949.71% | ||||||||||
| Net Margin | -9,134.08% | -11,897.00% | -16,914.56% | -22,054.52% | -24,470.64% | -27,621.34% | -41,698.67% | -82,765.55% | -260.82% | 8,349,600.00% | -813.55% | -1,003.58% | -10,301.62% | -784.57% | -2,443.03% | -23,916.86% | ||||||||||
| FCF Margin | -8,215.17% | -7,158.20% | -12,402.63% | -16,150.68% | -19,837.21% | -23,476.28% | -30,550.88% | -58,910.92% | -301.51% | 8,930,600.00% | -520.67% | -958.38% | -8,166.47% | -640.94% | -1,703.73% | -15,459.71% | ||||||||||
| Efficiency | ||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 0.66M | 0.66M | 475.27M | 919.65M | 1,029.07M | 1,134.24M | 1,068.67M | 999.79M | 934.49M | 875.47M | 842.71M | 807.00M | 851.33M | 900.71M | 835.33M | 764.10M | 699.42M | 645.67M | 660.47M | 833.53M | ||||||
| Asset Utilization RatioAsset Util. | 4.58 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.04 | 0.04 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | |||||||
| Leverage & Solvency | ||||||||||||||||||||||||||
| Interest Coverage RatioInterest Cover | -0.00M | -0.03M | -0.01M | -0.00M | ||||||||||||||||||||||
| Times Interest Earned | -0.00M | -0.03M | -0.01M | -0.00M | ||||||||||||||||||||||
| Valuation | ||||||||||||||||||||||||||
| Price to EarningsP/E | -48.10 | -49.26 | -45.79 | -22.64 | -32.10 | -25.89 | -21.23 | -15.55 | -15.76 | -16.81 | -13.49 | -9.43 | -13.41 | -9.09 | -5.80 | -8.52 | -12.18 | -26.78 | -25.69 | -48.84 | ||||||
| Price to SalesP/S | 0.00M | 0.01M | 0.01M | 0.00M | 0.01M | 0.01M | 0.01M | 0.01M | 41.10 | -1.40M | 109.73 | 58.17 | 877.48 | 210.13 | 627.54 | 0.01M | ||||||||||
| Price to BookP/B | 5.12 | 3.70 | 3.85 | 2.34 | 2.70 | 1.90 | 2.26 | 1.89 | 1.33 | 1.87 | 1.47 | 1.28 | 1.41 | 0.89 | 0.62 | 0.89 | 1.48 | 2.59 | 2.93 | 4.59 | ||||||
| Enterprise Value | 2,697.43M | 3,043.02M | 3,125.97M | 1,714.84M | 2,347.90M | 1,657.62M | 1,839.45M | 1,385.73M | 884.46M | 1,259.63M | 945.23M | 735.15M | 1,029.20M | 566.87M | 353.13M | 480.11M | 809.57M | 916.41M | 1,240.57M | 3,177.78M | ||||||
| EV to EBIT | -44.23 | -44.93 | -49.84 | -22.04 | -27.34 | -22.75 | -18.18 | -13.07 | -12.02 | -13.66 | -10.46 | -7.30 | -10.68 | -6.67 | -4.16 | -6.25 | -10.07 | -15.11 | -15.79 | -34.99 | ||||||
| EV to EBITDA | -44.23 | -44.93 | -49.84 | -22.04 | -27.34 | -22.75 | -18.18 | -13.07 | -12.02 | -13.66 | -10.46 | -7.30 | -10.68 | -6.67 | -4.16 | -6.25 | -10.07 | -15.11 | -15.79 | -34.99 | ||||||
| Market Capitalization | 2,925.99M | 3,323.14M | 3,245.41M | 1,822.58M | 2,702.55M | 1,809.42M | 2,000.72M | 1,531.63M | 1,035.78M | 1,403.36M | 1,098.10M | 869.28M | 1,181.56M | 691.15M | 446.67M | 594.05M | 901.14M | 1,470.93M | 1,882.63M | 4,088.72M | ||||||
| Price to FCFP/FCF | -53.48 | -81.88 | -62.45 | -30.92 | -39.60 | -30.46 | -28.98 | -21.85 | -13.63 | -15.71 | -21.08 | -13.20 | -15.69 | -11.94 | -6.07 | -10.74 | -14.51 | -32.78 | -36.83 | -75.56 | ||||||
| EV to FCF | -49.30 | -74.98 | -60.15 | -29.09 | -34.41 | -27.91 | -26.64 | -19.77 | -11.64 | -14.10 | -18.14 | -11.17 | -13.67 | -9.80 | -4.80 | -8.68 | -13.03 | -20.43 | -24.27 | -58.73 | ||||||
| EV to CFO | -50.70 | -76.64 | -63.57 | -30.04 | -35.50 | -29.04 | -27.40 | -20.20 | -11.73 | -14.12 | -18.78 | -11.17 | -13.71 | -9.80 | -4.82 | -8.69 | -13.03 | -20.43 | -24.27 | -58.73 | ||||||
| Return Ratios | ||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -9,157.66% | -11,944.09% | -14,969.21% | -21,318.08% | -24,968.60% | -28,794.86% | -44,768.58% | -89,117.65% | -291.95% | 9,219,600.00% | -903.00% | -1,013.67% | -3,794.57% | -3,722.07% | -1,105.21% | -11,351.11% | -3,914.38% | -866.14% | -2,619.67% | -25,949.71% | ||||||
| Return on Capital Employed [ROCE]ROCE | 940.54% | 1,541.48% | -88.80% | -30.74% | -30.72% | -27.96% | -33.83% | -39.43% | -40.02% | -44.13% | -44.96% | -46.84% | -47.20% | -43.82% | -45.97% | -46.89% | -49.05% | -48.82% | -47.00% | -39.66% | ||||||
| Return on Assets [ROA]ROA | -39,447.28% | -55,265.11% | -83.01% | -30.62% | -29.64% | -26.93% | -30.77% | -34.69% | -35.14% | -39.06% | -39.06% | -40.01% | -40.55% | -37.50% | -39.91% | -40.69% | -42.43% | -42.70% | -41.17% | -34.30% |